Trial · NCT00121238
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 21
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arthritis (Gr1) | Musculoskeletal and connective tissue disorders | Drug Treatment (Cilengitide) | 2 | 15 | |
| other | Increased aspartate aminotransferase (Gr1) | Blood and lymphatic system disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Constipation (Gr1) | Gastrointestinal disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Diarrhea (Gr1) | Gastrointestinal disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Dry eye syndrome (Gr1) | Eye disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Edema (Gr.1) | General disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Fatigue (Gr.1) | General disorders | Drug Treatment (Cilengitide) | 4 | 15 | |
| other | Flushing (Gr1) | General disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Headache (Gr.1) | General disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Decreased hemoglobin (gr1) | Blood and lymphatic system disorders | Drug Treatment (Cilengitide) | 2 | 15 | |
| other | Hyperglycemia NOS (Gr.1) | Metabolism and nutrition disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Hyperglycemia (Gr.1) | Metabolism and nutrition disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Hyponatremia (Gr.1) | General disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Memory impairment (Gr.1) | Nervous system disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Nausea Gr 1 | Gastrointestinal disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Rash (desquamating) (Gr.1) | Skin and subcutaneous tissue disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Toothache (Gr.1) | Gastrointestinal disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Dyspnea (Gr.2) | Respiratory, thoracic and mediastinal disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Lymphopenia (Gr.2) | Blood and lymphatic system disorders | Drug Treatment (Cilengitide) | 1 | 15 | |
| other | Osteonecrosis (Gr.2) | Musculoskeletal and connective tissue disorders | Drug Treatment (Cilengitide) | 1 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00121238/events